文献速递神经免疫认知障碍与痴呆

EB病毒与多发性硬化:从关联到机制到潜在治疗

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.
PubMed 文献 · Lancet Neurol · 2026-06-19

本文综述了EB病毒作为多发性硬化(MS)强而一致风险因素的血清学与流行病学证据,并探讨其与MS易感位点互作、驱动B细胞转录与分化改变、扩增神经侵袭性非典型B细胞并激活自身反应性T细胞的机制;据此提出疫苗、EBV特异性异体细胞毒性T淋巴细胞、靶向B细胞亚群的抗体与CAR-T及常规抗病毒等假设驱动的防治策略。

要点

  • EB病毒是MS强而一致的风险因素,机制涉及B细胞与T细胞互作。
  • EBV感染可扩增神经侵袭性非典型B细胞,后者富集于MS患者中枢神经系统炎症区域。
  • 疫苗、EBV特异性CTL、靶向B细胞亚群的抗体与CAR-T及抗病毒治疗是潜在方向。

核心结论

  • EB病毒与MS的关联已从流行病学走向机制解析,并支持发展针对EBV驱动自身免疫反应及免疫细胞进入中枢神经系统的治疗策略。

研究设计与样本

  • 本文为综述,基于血清学与流行病学研究及近期机制证据,汇总EBV与MS关联、机制与潜在治疗方向。

主要发现

  • EBV可与多个MS易感位点互作,改变B细胞的转录程序与分化轨迹。
  • EBV感染与神经侵袭性非典型B细胞扩增相关,此类细胞在MS患者炎症中枢神经系统区域富集并强效刺激自身反应性T细胞。
  • B细胞对EBV潜伏状态的调控失调,加上T细胞对EBV控制的细微缺陷,可能放大B细胞-T细胞互作并增加MS易感性。

临床怎么用

  • 这些认识支持开发旨在减轻EBV诱导的过度活跃自身免疫反应、并限制其进入中枢神经系统的假设驱动治疗策略。
  • 在研策略包括预防性与治疗性疫苗、EBV特异性异体细胞毒性T淋巴细胞、靶向EBV诱导并迁移入中枢神经系统的B细胞亚群的抗体与CAR-T疗法,以及常规抗病毒治疗。
  • 上述途径可能为MS的预防与治疗提供新视角,并有助于厘清EBV是否影响MS发病后的疾病活动度与残疾累积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epstein-Barr virus, a widespread herpesvirus that establishes lifelong latency after primary infection, has emerged in serological and epidemiological studies as a strong and consistent risk factor for multiple sclerosis. RECENT DEVELOPMENTS: Emerging evidence indicates that Epstein-Barr virus can interact with several multiple sclerosis susceptibility loci to modify the transcriptional programmes and differentiation trajectories of B cells. Specifically, Epstein-Barr virus infection has been associated with the expansion of neuroinvasive, atypical B cells, which are enriched in inflamed CNS compartments in people with multiple sclerosis and exhibit a strong capacity to stimulate autoreactive T cells. Dysregulation of Epstein-Barr virus latency by B cells, together with subtle deficiencies in T-cell-mediated control of Epstein-Barr virus, might further amplify the effect of these B cell-T cell interactions and predispose individuals to multiple sclerosis. WHERE NEXT?: These insights support the development of hypothesis-driven therapeutic strategies aimed at attenuating hyperactive autoimmune responses induced by Epstein-Barr virus and the autoimmune responses' access to the CNS. Strategies under investigation include prophylactic and therapeutic vaccines; allogeneic cytotoxic T lymphocytes specific for Epstein-Barr virus and designed to eliminate virus-infected cells; antibody-based and chimeric antigen receptor T-cell-based therapies targeting B-cell subsets induced by Epstein-Barr virus and migrate into the CNS; and conventional antiviral treatments. Together, these approaches might open new perspectives for both prevention and treatment of multiple sclerosis. Furthermore, they might help to clarify whether Epstein-Barr virus infection influences not only susceptibility to multiple sclerosis, but also disease activity and disability accrual after disease onset.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Lünemann JD, Münz C. Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies. Lancet Neurol. 2026. PMID: 42320500. doi:10.1016/S1474-4422(26)00177-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。